These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

448 related articles for article (PubMed ID: 29800932)

  • 61. Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With Triple-Negative Breast Cancer: A Phase 3 Randomized Clinical Trial.
    Yu KD; Ye FG; He M; Fan L; Ma D; Mo M; Wu J; Liu GY; Di GH; Zeng XH; He PQ; Wu KJ; Hou YF; Wang J; Wang C; Zhuang ZG; Song CG; Lin XY; Toss A; Ricci F; Shen ZZ; Shao ZM
    JAMA Oncol; 2020 Sep; 6(9):1390-1396. PubMed ID: 32789480
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer.
    Abraham JE; Pinilla K; Dayimu A; Grybowicz L; Demiris N; Harvey C; Drewett LM; Lucey R; Fulton A; Roberts AN; Worley JR; Chhabra A; Qian W; Vallier AL; Hardy RM; Chan S; Hickish T; Tripathi D; Venkitaraman R; Persic M; Aslam S; Glassman D; Raj S; Borley A; Braybrooke JP; Sutherland S; Staples E; Scott LC; Davies M; Palmer CA; Moody M; Churn MJ; Newby JC; Mukesh MB; Chakrabarti A; Roylance RR; Schouten PC; Levitt NC; McAdam K; Armstrong AC; Copson ER; McMurtry E; Tischkowitz M; Provenzano E; Earl HM
    Nature; 2024 May; 629(8014):1142-1148. PubMed ID: 38588696
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Eribulin-based neoadjuvant chemotherapy for triple-negative breast cancer patients stratified by homologous recombination deficiency status: a multicenter randomized phase II clinical trial.
    Masuda N; Bando H; Yamanaka T; Kadoya T; Takahashi M; Nagai SE; Ohtani S; Aruga T; Suzuki E; Kikawa Y; Yasojima H; Kasai H; Ishiguro H; Kawabata H; Morita S; Haga H; Kataoka TR; Uozumi R; Ohno S; Toi M
    Breast Cancer Res Treat; 2021 Jul; 188(1):117-131. PubMed ID: 33763789
    [TBL] [Abstract][Full Text] [Related]  

  • 64. SOLTI NeoPARP: a phase II randomized study of two schedules of iniparib plus paclitaxel versus paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cancer.
    Llombart-Cussac A; Bermejo B; Villanueva C; Delaloge S; Morales S; Balmaña J; Amillano K; Bonnefoi H; Casas A; Manso L; Roché H; Gonzalez-Santiago S; Gavilá J; Sánchez-Rovira P; Di Cosimo S; Harbeck N; Charpentier E; Garcia-Ribas I; Radosevic-Robin N; Aura C; Baselga J
    Breast Cancer Res Treat; 2015 Nov; 154(2):351-7. PubMed ID: 26536871
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Pembrolizumab in combination with nab-paclitaxel for the treatment of patients with early-stage triple-negative breast cancer - A single-arm phase II trial (NeoImmunoboost, AGO-B-041).
    Fasching PA; Hein A; Kolberg HC; Häberle L; Uhrig S; Rübner M; Belleville E; Hack CC; Fehm TN; Janni W; Hartmann A; Erber R; Theuser AK; Brucker SY; Hartkopf AD; Untch M
    Eur J Cancer; 2023 May; 184():1-9. PubMed ID: 36871424
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Pathological response and clinical outcomes in operable triple-negative breast cancer with cisplatin added to standard neoadjuvant chemotherapy.
    Georgy JT; Singh A; John AO; Joel A; Andrews AG; Thumaty DB; Rebekah G; Sigamani E; Chandramohan J; Manipadam MT; Cherian AJ; Abraham DT; Paul MJ; Balakrishnan R; Backianathan S; Chacko RT
    Klin Onkol; 2021; 34(1):49-55. PubMed ID: 33657819
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancer.
    Schneeweiss A; Michel LL; Möbus V; Tesch H; Klare P; Hahnen E; Denkert C; Kast K; Pohl-Rescigno E; Hanusch C; Link T; Untch M; Jackisch C; Blohmer JU; Fasching PA; Solbach C; Schmutzler RK; Huober J; Rhiem K; Nekljudova V; Lübbe K; Loibl S;
    Eur J Cancer; 2022 Jan; 160():100-111. PubMed ID: 34801353
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Carboplatin plus taxanes are non-inferior to epirubicin plus cyclophosphamide followed by taxanes as adjuvant chemotherapy for early triple-negative breast cancer.
    Du F; Wang W; Wang Y; Li M; Zhu A; Wang J; Cai R; Ma F; Fan Y; Li Q; Zhang P; Todorovic V; Yuan P; Xu B
    Breast Cancer Res Treat; 2020 Jul; 182(1):67-77. PubMed ID: 32394350
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Multicentric neoadjuvant pilot Phase II study of cetuximab combined with docetaxel in operable triple negative breast cancer.
    Nabholtz JM; Chalabi N; Radosevic-Robin N; Dauplat MM; Mouret-Reynier MA; Van Praagh I; Servent V; Jacquin JP; Benmammar KE; Kullab S; Bahadoor MR; Kwiatkowski F; Cayre A; Abrial C; Durando X; Bignon YJ; Chollet P; Penault-Llorca F
    Int J Cancer; 2016 May; 138(9):2274-80. PubMed ID: 26649807
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Analysis of the factors affecting pathologic complete response to neoadjuvant chemotherapy in breast cancer patients].
    Sun B; Song ST; Jiang ZF; Wang T; Zhang SH; Meng XY; Li XB; Yu CZ; Wu SK
    Zhonghua Zhong Liu Za Zhi; 2013 Jan; 35(1):38-42. PubMed ID: 23648298
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Unfavorable pathological complete response rate of neoadjuvant chemotherapy epirubicin plus taxanes for locally advanced triple-negative breast cancer.
    Yin Y; Zhang P; Xu BH; Zhang BL; Li Q; Yuan P; Cai RG; Wang JY; Wang X; Xu XZ
    J Huazhong Univ Sci Technolog Med Sci; 2013 Apr; 33(2):262-265. PubMed ID: 23592141
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers.
    Denkert C; von Minckwitz G; Brase JC; Sinn BV; Gade S; Kronenwett R; Pfitzner BM; Salat C; Loi S; Schmitt WD; Schem C; Fisch K; Darb-Esfahani S; Mehta K; Sotiriou C; Wienert S; Klare P; André F; Klauschen F; Blohmer JU; Krappmann K; Schmidt M; Tesch H; Kümmel S; Sinn P; Jackisch C; Dietel M; Reimer T; Untch M; Loibl S
    J Clin Oncol; 2015 Mar; 33(9):983-91. PubMed ID: 25534375
    [TBL] [Abstract][Full Text] [Related]  

  • 73. TBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-Cyclophosphamide in Germline
    Tung N; Arun B; Hacker MR; Hofstatter E; Toppmeyer DL; Isakoff SJ; Borges V; Legare RD; Isaacs C; Wolff AC; Marcom PK; Mayer EL; Lange PB; Goss AJ; Jenkins C; Krop IE; Winer EP; Schnitt SJ; Garber JE
    J Clin Oncol; 2020 May; 38(14):1539-1548. PubMed ID: 32097092
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Pathological Response in a Triple-Negative Breast Cancer Cohort Treated with Neoadjuvant Carboplatin and Docetaxel According to Lehmann's Refined Classification.
    Echavarria I; López-Tarruella S; Picornell A; García-Saenz JÁ; Jerez Y; Hoadley K; Gómez HL; Moreno F; Monte-Millan MD; Márquez-Rodas I; Alvarez E; Ramos-Medina R; Gayarre J; Massarrah T; Ocaña I; Cebollero M; Fuentes H; Barnadas A; Ballesteros AI; Bohn U; Perou CM; Martin M
    Clin Cancer Res; 2018 Apr; 24(8):1845-1852. PubMed ID: 29378733
    [No Abstract]   [Full Text] [Related]  

  • 75. Phase II open-label study of bevacizumab combined with neoadjuvant anthracycline and taxane therapy for locally advanced breast cancer.
    Clavarezza M; Turazza M; Aitini E; Saracchini S; Garrone O; Durando A; De Placido S; Bisagni G; Levaggi A; Bighin C; Restuccia E; Scalamogna R; Galli A; Del Mastro L
    Breast; 2013 Aug; 22(4):470-5. PubMed ID: 23642526
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Significance of Tumor-Infiltrating Lymphocytes and the Expression of Topoisomerase IIα in the Prediction of the Clinical Outcome of Patients with Triple-Negative Breast Cancer after Taxane-Anthracycline-Based Neoadjuvant Chemotherapy.
    Rao N; Qiu J; Wu J; Zeng H; Su F; Qiu K; Wu J; Yao H
    Chemotherapy; 2017; 62(4):246-255. PubMed ID: 28472798
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Neoadjuvant immunotherapy and chemotherapy regimens for the treatment of high-risk, early-stage triple-negative breast cancer: a systematic review and network meta-analysis.
    Cortes J; Haiderali A; Huang M; Pan W; Schmid P; Akers KG; Park JE; Frederickson AM; Fasching PA; O'Shaughnessy J
    BMC Cancer; 2023 Aug; 23(1):792. PubMed ID: 37612624
    [TBL] [Abstract][Full Text] [Related]  

  • 78. A Phase II trial of docetaxel and carboplatin administered every 2 weeks as preoperative therapy for stage II or III breast cancer: NCCTG study N0338.
    Roy V; Pockaj BA; Allred JB; Apsey H; Northfelt DW; Nikcevich D; Mattar B; Perez EA
    Am J Clin Oncol; 2013 Dec; 36(6):540-4. PubMed ID: 22868240
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Neo-adjuvant doxorubicin and cyclophosphamide followed by paclitaxel in triple-negative breast cancer among BRCA1 mutation carriers and non-carriers.
    Paluch-Shimon S; Friedman E; Berger R; Papa M; Dadiani M; Friedman N; Shabtai M; Zippel D; Gutman M; Golan T; Yosepovich A; Catane R; Modiano T; Kaufman B
    Breast Cancer Res Treat; 2016 May; 157(1):157-65. PubMed ID: 27113739
    [TBL] [Abstract][Full Text] [Related]  

  • 80. BRCAness and Prognosis in Triple-Negative Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.
    Tanino H; Kosaka Y; Nishimiya H; Tanaka Y; Minatani N; Kikuchi M; Shida A; Waraya M; Katoh H; Enomoto T; Sengoku N; Kajita S; Hoffman RM; Watanabe M
    PLoS One; 2016; 11(12):e0165721. PubMed ID: 27935989
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.